In this study, we applied a cut-off value of >10% for EGFR and CK5/6 assessment based on our previous experience [36], and on mRNA/miRNA data which confirm the molecular clusterization of these two groups according to such an immunohistochemical evaluation (Gasparini P, et al. microRNA expression profiling identifies a 4-microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancer. Here, EGFR is linked to triple-negative breast carcinoma.